Drug Sponsors

Dendreon files for bankruptcy protection

Wednesday, November 12, 2014 03:30 PM

Dendreon, a Seattle-based biotechnology company, and its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on Nov. 10.

More... »


Consort Medical acquires Aesica

Wednesday, November 12, 2014 03:26 PM

Consort has completed its acquisition of Aesica Holdco. The acquisition is directly in line with Consort's articulated strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.

More... »


Report: Big biopharma would rather ‘make than buy’

Wednesday, November 12, 2014 03:21 PM

Global and generic biopharma companies will continue to prefer in-house manufacturing to outsourcing for the most strategic elements of their businesses, according to a report by PharmSource Information Services, a Virginia-based provider of market intelligence for the global contract biopharma industry.

More... »

UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »

Perrigo to acquire Omega Pharma for $4.5 billion

Friday, November 7, 2014 01:26 PM

Perrigo, a Dublin, Ireland-based global provider of healthcare products, will acquire Omega Pharma, an OTC healthcare company headquartered in Nazareth, Belgium, for $4.5 billion, including a $3.1 billion purchase price plus assumption of $1.4 billion in debt. The transaction will enhance Perrigo's OTC product offering and expand its distribution through Omega's strong established platform. 

More... »

GVK BIO to acquire Vanta Bioscience

Friday, November 7, 2014 01:09 PM

GVK BIO, a Hyderabad, India-based discovery R&D organization, will acquire Vanta Bioscience, a full-service preclinical GLP toxicology and safety assessment CRO operating from Chennai, India.

More... »

MedImmune acquires Definiens, strengthens immuno-oncology capabilities

Wednesday, November 5, 2014 12:55 PM

AstraZeneca’s global biologics R&D arm MedImmune has entered into an agreement to acquire Germany-based Definiens, a privately held company focused on imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumor tissue.

More... »

Bristol-Myers Squibb signs option agreement to acquire Galecto Biotech

Wednesday, November 5, 2014 12:50 PM

Bristol-Myers Squibb has entered into an agreement with the exclusive option to acquire Denmark’s Galecto Biotech and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in phase I development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. Total aggregate payments under the agreement have the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.

More... »

AstraZeneca has acquired Almirall’s respiratory business

Wednesday, November 5, 2014 12:45 PM

Almirall, a global company based in Barcelona dedicated to providing valuable medicines through its R&D, agreements and alliances, has completed the transaction to transfer to AstraZeneca the rights to Almirall's respiratory franchise after all closing conditions have been satisfied. AZ now will own the rights for the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies.

More... »

PDR, LDM Group merge

Wednesday, November 5, 2014 12:42 PM

PDR Network, a Montvale, N.J.-based provider of drug information and prescriber communications, has merged with LDM Group, a St. Louis, Mo.-based provider of behavior-based patient and consumer health information.  

More... »

CenterWatch
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs